Acoramidis (AG10)
Sponsors
Eidos Therapeutics Inc., Eidos Therapeutics, a BridgeBio company
Conditions
Amyloid CardiomyopathyAmyloid Cardiomyopathy, Transthyretin-RelatedAmyloidogenic Transthyretin (ATTR) AmyloidosisAmyloidosisAmyloidosis in Transthyretin (TTR)Amyloidosis, FamilialAmyloidosis, Hereditary, Transthyretin-RelatedCardiomyopathies
Phase 3
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Active, not recruitingNCT04988386
Start: 2021-10-27End: 2028-05-15Updated: 2025-10-14
An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
Active, not recruitingCTIS2024-515092-36-00
Start: 2022-02-14Target: 215Updated: 2025-07-31
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)
RecruitingCTIS2024-513547-82-00
Start: 2025-03-11Target: 314Updated: 2025-12-11
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Not yet recruitingNCT07116473
Start: 2026-11-01End: 2037-12-01Target: 250Updated: 2026-08-11
A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
Not yet recruitingCTIS2024-513676-18-00
Target: 92Updated: 2026-01-14